ArticleClinical neuroradiology2026
In-Vitro Comparison of Cyclic Aspiration and Superbore Aspiration Catheters to Conventional 6Fr Aspiration for LVO Stroke.
Article in Clinical neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim was to compare conventional aspiration (CA) using 6Fr catheters with two emerging techniques: Superbore Aspiration Catheters (SAC), which have a 0.088″ lumen, and Cyclic Aspiration (CycA), which combines a 6Fr aspiration catheter with a cyclic pressure waveform, both aiming to improve revascularization and minimize distal embolization.
methodsOvine blood clots (soft, mixed, stiff) were lodged in the ICA and M1 of an in-vitro thrombectomy model. A proprietary cyclic aspiration waveform was optimized. React 71 was used for the CA and CycA groups; Millipede88 was used for SAC. Key endpoints for assessing differences between techniques were First Pass Effect (FPE), Complete Clot Ingestion (CCI), Final Complete Revascularization (mTICI 2c/3 within three passes), and distal emboli rates.
resultsSAC had the highest rates of FPE (ICA; 32%, MCA; 88%) and Final Complete Revascularization (ICA; 91%, MCA; 91%). Compared to CA, CycA was associated with numerically higher rates of CCI (26% vs 9%) and FPE (29% vs 21%) in ICA occlusions. CycA had similar rates of CCI (62% vs 59%) and a lower rate of FPE (62% vs 71%) in MCA occlusions, compared to CA. CycA and CA had similar rates of Final Complete Revascularization (ICA; 79% vs 79%, MCA; 79% vs 82%). SAC had the least distal emboli in both MCA and ICA occlusions. CycA had the most distal emboli overall, particularly for ICA occlusions.
conclusionSAC demonstrated superior revascularization performance in-vitro compared to CycA and CA, improving both FPE and Final Complete Revascularization. CycA was associated with higher observed rates of CCI and FPE in the ICA, but generated more distal emboli.
Indexed as
Identifiers
42747441What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.